Startseite › Nichtkleinzelliges Lungenkarzinom › Kentucky › Louisville
Klinische Studien zu Nichtkleinzelliges Lungenkarzinom in Louisville, KY
22 Studien zu Nichtkleinzelliges Lungenkarzinom suchen Teilnehmer an Standorten in und um Louisville (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
A Study of ZW251 in Participants With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- Norton Cancer Institute, Louisville
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Teilnehmer gesuchtPhase 1/2
- James Graham Brown Cancer Center (Melanoma/NSCLC), Louisville
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Teilnehmer gesuchtPhase 3
- Baptist Health Louisville, Louisville
- Baptist Health Floyd, New Albany · 4 mi entfernt
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Teilnehmer gesuchtPhase 3
- Norton Cancer Institute Downtown, Louisville
- Norton Cancer Institute, Downtown, Louisville
- Norton Hospital, Louisville
- und 4 weitere
Pan-tumor MRD Study
Teilnehmer gesuchtBeobachtungsstudie
- Baptist Health Louisville, Louisville
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Teilnehmer gesuchtPhase 3
- The University of Louisville, James Graham Brown Cancer Center, Louisville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Teilnehmer gesuchtPhase 1
- Norton Cancer Institute, Louisville
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Teilnehmer gesuchtPhase 3
- Research Site, Louisville
- Research Site, Louisville
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Teilnehmer gesuchtPhase 2/3
- University of Louisville, Louisville
- Local Institution - 007-388-A, Louisville
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Teilnehmer gesuchtPhase 1/2
- Norton Cancer Institute Research, Louisville
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Norton Cancer Institute PARENT, Louisville
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Teilnehmer gesuchtPhase 3
- Research Site, Louisville
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Teilnehmer gesuchtPhase 1/2
- Norton Cancer Institute, Louisville
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Teilnehmer gesuchtPhase 1
- Norton Cancer Institute, Louisville
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Teilnehmer gesuchtPhase 2
- University of Louisville, Louisville
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Teilnehmer gesuchtPhase 1
- Norton Cancer Institute /ID# 248903, Louisville
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Teilnehmer gesuchtPhase 1/2
- University of Louisville, Louisville
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Teilnehmer gesuchtPhase 3
- Research Site, Louisville
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Teilnehmer gesuchtPhase 2
- University Medical Center, lnc.:DBA University of Louisville Hospital, Louisville
- University of Louisville, Louisville
- UofL Health Brown Cancer Center, Louisville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Research Site 115, Louisville
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Teilnehmer gesuchtPhase 1
- Research Site, Louisville
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
Teilnehmer gesucht
- James Graham Brown Cancer Center, Louisville
Nichtkleinzelliges Lungenkarzinom-Studien in anderen Städten
- Houston, TX145 Studien
- New York City, NY121 Studien
- Arlington, VA104 Studien
- Nashville, TN97 Studien
- Boston, MA90 Studien
- Los Angeles, CA87 Studien
- St. Louis, MO73 Studien
- Chicago, IL61 Studien
- Baltimore, MD60 Studien
- San Antonio, TX59 Studien
- Columbus, OH57 Studien
- Washington, DC55 Studien
Weitere Studien in Louisville
- Adipositas17 Studien
- Übergewicht15 Studien
- Krebs (alle Arten)14 Studien
- Herzinsuffizienz13 Studien
- Akute myeloische Leukämie12 Studien
- Multiples Myelom12 Studien
- Eierstockkrebs12 Studien
- Brustkrebs11 Studien
- Plattenepithelkarzinom im Kopf-Hals-Bereich11 Studien
- Lungenkrebs11 Studien
- Melanom10 Studien
- Prostatakrebs10 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 06.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.